Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

Authors: Marin, D  Khorashad, JS  Foroni, L  Milojkovic, D  Szydlo, R  Reid, AG  Rezvani, K  Bua, M  Goldman, JM  Apperley, JF 
Citation: Marin D, etal., Br J Haematol. 2009 May;145(3):373-5. doi: 10.1111/j.1365-2141.2009.07646.x. Epub 2009 Mar 12.
Pubmed: (View Article at PubMed) PMID:19344397
DOI: Full-text: DOI:10.1111/j.1365-2141.2009.07646.x

BCR-ABL1 transcript numbers were monitored in 161 patients who started treatment with imatinib early after diagnosis of chronic myeloid leukaemia in chronic phase and achieved complete cytogenetic responses (CCyR). A confirmed doubling in BCR-ABL1/ABL1 transcript levels was found to be a significant factor for predicting loss of CCyR [relative risk (RR) 8.3, P < 0.0001] and progression to advanced phase (RR 0.07, P = 0.03) provided that the eventual BCR-ABL1/ABL1 transcript level exceeded 0.05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11038809
Created: 2016-02-26
Species: All species
Last Modified: 2016-02-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.